Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 6/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 7/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255847 | 0.95 | LOXL2 (0.55) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL9037490 | 0.89 | LOXL2 (0.60) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL17969036 | 0.81 | LOXL2 (0.61) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL2049247 | 0.81 | LOXL2 (0.56) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL29594271 | 0.81 | LOXL2 (0.56) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL1287509 | 0.81 | LOXL2 (0.56) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL6214405 | 0.81 | LOXL2 (0.56) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL5776752 | 0.81 | LOXL2 (0.67) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL22971168 | 0.81 | LOXL2 (0.56) | LOXL2AGXTDRD2DRD3DRD1 | |
| SCHEMBL4149836 | 0.80 | LOXL2 (0.64) | LOXL2AGXTDRD2HTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| EP-1278741-B1 | MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | LOXL2 1524/4885AGXT 4251/4885DRD2 476/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | LOXL2 1524/4885AGXT 4251/4885DRD2 476/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | LOXL2 1524/4885AGXT 4251/4885DRD2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.